HIV Immunovirology Section
Tae-Wook Chun, Ph.D.
Chief, HIV Immunovirology Section
Contact: For contact information, search the NIH Enterprise Directory.
Major Areas of Research
- Persistence of viral reservoirs in HIV-infected individuals receiving antiretroviral therapy.
- Viral dynamics and immunologic control of HIV replication in infected individuals.
- Development of therapeutic strategies aimed at achieving sustained virologic control in HIV-infected individuals in the absence of antiretroviral therapy.
Our research program focuses on 1) delineating the role of viral reservoirs in the pathogenesis of HIV disease; 2) examining host and viral factors that contribute to the maintenance of HIV reservoirs; and 3) developing therapeutic strategies aimed at achieving durable virologic control in infected individuals in the absence of antiretroviral therapy. Our research program utilizes Bench-to-Bedside approaches. We conduct comprehensive genetic, immunologic, and virologic analyses of CD4+ and CD8+ T cells in diverse cohorts of HIV-infected individuals in order to address fundamental pathogenic questions, such as elucidating mechanisms of viral persistence, the role of the host immunity in containment of viral replication and evaluating promising novel therapeutic agents in both ex vivo and in vivo settings. Based on findings from bench research, we also conduct phase I clinical trials in close collaboration with the NIAID HIV clinic, with the ultimate goal of developing safe, effective, and scalable therapeutic strategies that would allow HIV-infected individuals to control viral replication in the absence of daily antiretroviral drugs.
Ph.D., The Johns Hopkins University School of Medicine, Baltimore, MD
Dr. Chun received his Ph.D. from the Biochemistry, Cellular, and Molecular Biology Graduate Program from the Johns Hopkins University School of Medicine where he the first to discover latently infected, resting CD4+ T cells in HIV-infected individuals. In 1997, he was recruited by Dr. Anthony Fauci in the Laboratory of Immunoregulation at NIAID to pursue his studies on HIV persistence in infected individuals receiving antiretroviral therapy as a post-doctoral research fellow. In 2001, Dr. Chun was appointed to the position of staff scientist and, in 2016, he became a tenure track investigator after being selected from the Trans-NIH Earl Stadtman Tenure-Track Program. Dr. Chun received full tenure in 2020.
Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection, NCT04811040
Combination Therapy With VRC-HIVMAB060-00-AB (VRC01) and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions, NCT03831945
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals, NCT03571204
Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals, NCT03225118
Vedolizumab (Anti-alpha4beta7) in Subjects with HIV Infection Undergoing Analytical Treatment Interruption, NCT02788175
Therapeutic Vaccine for HIV, NCT01859325
VRC-HIVMAB060-00-AB (VRC01) in People with Chronic HIV Infection Undergoing Analytical Treatment Interruption, NCT02471326
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Primary and Chronic HIV-Infected Patients, NCT00039689
Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, Tolstenko J, McCormack G, Whitehead EJ, Schneck RF, Proschan MA, Benko E, Kovacs C, Oguz C, Seaman MS, Caskey M, Nussenzweig MC, Fauci AS, Moir S, and Chun TW. Combination anti-HIV antibodies provide sustained virological suppression. Nature. 2022 June 1. doi: 10.1038/s41586-022-04797-9.
Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, Turroja M, Butler A, Ramos V, Seaman MS, Reeves JD, Petroupoulos CJ, Shimeliovich I, Gazumyan A, Jiang CS, Jilg N, Scheid JF, Gandhi R, Walker BD, Sneller MC, Fauci A, Chun TW, Caskey M, Nussenzweig MC. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022 Apr 13.
Blazkova J, Gao F, Marichannegowda MH, Justement JS, Shi V, Whitehead EJ, Schneck RF, Huiting ED, Gittens K, Cottrell M, Benko E, Kovacs C, Lack J, Sneller MC, Moir S, Fauci AS, Chun TW. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat Med. 2021 Nov;27(11):1893-1898.
Blazkova J, Refsland EW, Clarridge KE, Shi V, Justement JS, Huiting ED, Gittens KR, Chen X, Schmidt SD, Liu C, Doria-Rose N, Mascola JR, Heredia A, Moir S, Chun TW. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. J Clin Invest. 2019 Nov 1;129(11):4832-4837.
Wang CY, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn S, Blazkova J, Clarridge KE, Su HW, Lin CY, Tseng FC, Lai A, Yang FH, Lin CH, Tseng W, Lin HY, Finstad CL, Wong-Staal F, Hanson CV, Chun TW, Liao MJ. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. N Engl J Med. 2019 Apr 18;380(16):1535-1545.
Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 2018 Jan 11;14(1):e1006792.
We study persistence of viral reservoirs in HIV-infected individuals receiving antiretroviral therapy; viral dynamics and immunologic control of HIV replication in infected individuals; development of therapeutic strategies aimed at achieving sustained virologic control in HIV-infected individuals in the absence of antiretroviral therapy.